Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | ASPH | Q12797 | 2/20 | 0.55 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.55 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.55 |
| ▸ | KDM5A | P29375 | 2/20 | 0.55 |
| ▸ | KDM3A | Q9Y4C1 | 2/20 | 0.55 |
| ▸ | KDM6B | O15054 | 1/20 | 0.55 |
| ▸ | TET3 | O43151 | 1/20 | 0.55 |
| ▸ | KDM4A | O75164 | 1/20 | 0.55 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | KDM5C | P41229 | 1/20 | 0.55 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.55 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.55 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.55 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.55 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.55 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.55 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12258250 | 0.87 | KDM4E (0.56) | KDM4EALDH1A1ASPHKDM8KDM4C | |
| SCHEMBL10872507 | 0.85 | KDM4E (0.54) | KDM4EALDH1A1ASPHKDM8KDM4C | |
| SCHEMBL29272073 | 0.85 | KDM4E (0.52) | KDM4EALDH1A1ASPHKDM8KDM4C | |
| SCHEMBL31032261 | 0.85 | KDM4E (0.52) | KDM4EALDH1A1ASPHKDM8KDM4C | |
| SCHEMBL6169475 | 0.85 | ALDH1A1 (0.47) | KDM4EALDH1A1ASPHKDM8KDM4C | |
| SCHEMBL25687802 | 0.85 | KDM4E (0.55) | KDM4EALDH1A1ASPHKDM8KDM4C | |
| SCHEMBL10204249 | 0.83 | RAF1 (0.43) | KDM4EALDH1A1ASPHKDM8KDM4C | |
| SCHEMBL18542887 | 0.83 | KDM4C (0.40) | KDM4EALDH1A1ASPHKDM8KDM4C | |
| SCHEMBL23760240 | 0.82 | KDM4E (0.57) | KDM4EALDH1A1ASPHKDM8KDM4C | |
| SCHEMBL31032209 | 0.82 | KDM4E (0.49) | KDM4EALDH1A1ASPHKDM8KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11624089-B2 | Cyanine dyes | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2023-04-11 | — | — | US | disclosed |
| US-20230023075-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CHEMOCENTRYX, INC. | 2023-01-26 | — | — | US | disclosed |
| WO-2022272060-A1 | EP2 ANTAGONIST COMPOUNDS | RESERVOIR NEUROSCIENCE, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-11304952-B2 | Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor | CHEMOCENTRYX, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-20220112166-A1 | Selective JAK2 Pseudokinase Ligands and Methods of Use | YALE UNIVERSITY | 2022-04-14 | — | — | US | disclosed |
| CN-111449083-A | Low-temperature acidic cleaning composition and preparation method and application thereof | 上海柯珑清洁技术有限公司 | 2020-07-28 | — | — | CN | disclosed |
| US-20200232023-A1 | CYANINE DYES | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | 2020-07-23 | — | — | US | disclosed |
| US-10464934-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| EP-1654268-A2 | LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2006-05-10 | — | — | EP | disclosed |
| CN-1681832-A | Lincomycin derivatives possessing antibacterial activity | VICURON PHARM INC (US) | 2005-10-12 | — | — | CN | disclosed |
| EP-1529052-A2 | LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2005-05-11 | — | — | EP | disclosed |
| WO-2005007665-A2 | LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20040230046-A1 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. | 2004-11-18 | — | — | US | disclosed |
| US-20040116690-A1 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004016632-A2 | LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS, INC. (US) | 2004-02-26 | — | — | WO | disclosed |
| EP-0053789-B1 | 2-PYRIDINECARBOXAMIDE DERIVATIVE, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITION, USEFUL AS AN ANTI-ALLERGIC AGENT | Tanabe Seiyaku Co., Ltd. (JP) | 1985-03-27 | — | — | EP | disclosed |
| US-4404214-A | 2-Pyridinecarboxamide derivatives compositions containing same and method of using same | TANABE SEIYAKU CO., LTD. (JP) | 1983-09-13 | — | — | US | disclosed |
| EP-0053789-A1 | 2-Pyridinecarboxamide derivative, process for preparing same and pharmaceutical composition, useful as an anti-allergic agent | Tanabe Seiyaku Co., Ltd. (JP) | 1982-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464934-B2 | Substituted tetrahydropyrans as CCR2 modulators | CCR2, CCR1, CCR5 | KDM4E 4548/4885ALDH1A1 1316/4885ASPH 3541/4885 |
| US-20040230046-A1 | Lincomycin derivatives possessing antibacterial activity | NRDC, NISCH, CLSPN | KDM4E 3921/4885ALDH1A1 2737/4885ASPH 3214/4885 |
| US-11624089-B2 | Cyanine dyes | ABCG2, IK, ACR | KDM4E 2687/4885ALDH1A1 1447/4885ASPH 411/4885 |
| US-20200232023-A1 | CYANINE DYES | ABCG2, IK, ACR | KDM4E 2687/4885ALDH1A1 1447/4885ASPH 411/4885 |
| US-20220112166-A1 | Selective JAK2 Pseudokinase Ligands and Methods of Use | JAK2, JAK1, MCL1 | KDM4E 1336/4885ALDH1A1 3690/4885ASPH 2140/4885 |
| US-20230023075-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CCR2, PDCD1LG2, CD274 | KDM4E 3769/4885ALDH1A1 1295/4885ASPH 4473/4885 |
| US-11304952-B2 | Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor | CCR2, PDCD1LG2, CD274 | KDM4E 3769/4885ALDH1A1 1295/4885ASPH 4473/4885 |
| US-20230263784-A1 | COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | CCR2, PDCD1LG2, CD274 | KDM4E 3769/4885ALDH1A1 1295/4885ASPH 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.